News | Pacemakers | May 09, 2016

New Data Showcases Long-term Benefits of Nanostim Leadless Pacemaker

Three presentations at HRS 2016 highlight the retrievability of the Nanostim leadless pacemaker, the absence of certain complications and improved patient quality of life

Nanostim, leadless pacemaker

May 9, 2016 — New data presented at the Heart Rhythm Society's (HRS) annual meeting highlighted the long-term safety of the retrievability of the St. Jude Medical Nanostim leadless pacemaker. Two additional presentations also showed that the Nanostim leadless pacemaker is associated with reduced rates of acute and mid-term complications compared to traditional pacemakers with leads and can improve quality of life for patients.

The option to be able to retrieve a leadless pacemaker over time is important for patients with changing medical conditions which may necessitate removal of implanted devices. New data presented at HRS 2016 demonstrated that within the LEADLESS II IDE study and the LEADLESS Observational Study across Europe, the Nanostim leadless pacemaker was successfully retrieved in 14 patients up to 3.2 years post-implantation without any serious adverse events.

“Device retrieval is a desirable feature of implanted leadless pacemakers because it offers physicians options in the future so that we can provide optimal care for our patients,” said Vivek Reddy, M.D., primary investigator of the LEADLESS II study and the director of electrophysiology from Mount Sinai Hospital in New York, N.Y. “We’ve now shown that for patients requiring device upgrades or new leadless pacing options, late retrievability — even up to three years — is possible with the Nanostim leadless pacemaker.”
In two additional clinical presentations, data showed fewer acute and mid-term complications with the Nanostim leadless pacemaker compared to traditional transvenous pacemakers and improved quality of life immediately after implant and over time. 

In a new analysis from LEADLESS II study data and real-world claims data from the Truven Health MarketScan database, which tracks U.S. health care claims and Medicare supplemental insurance encounters, an international group of researchers found that the Nanostim leadless pacemaker resulted in fewer complications in both the first month post-implant as well as in the first two years post-implant. The data also demonstrated a growing benefit over time with patients receiving a leadless pacemaker, showing a clear advantage in combating infections and lead-related adverse events.

The Nanostim leadless pacemaker operates like a traditional pacemaker, but is 10 percent the size of a conventional pacemaker. Implanted via the femoral vein with an 18 French introducer, the smallest available for a leadless pacemaker, the device offers patients a minimally-invasive option for pacemaker delivery, potentially reducing overall complications including device-related infection of the pocket and lead failure. The Nanostim leadless pacemaker received CE mark approval in August 2013. To date, more than 1,100 Nanostim leadless pacemakers have been implanted worldwide. The Nanostim leadless pacemaker is undergoing a clinical study in the U.S. under an FDA-approved investigational device exemption.

For more information: 

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init